Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,187
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Patritumab deruxtecan
Daiichi Sankyo Europe GmbH
Locally Advanced or Metastatic Solid Tumors
1 trial -
Quizartinib
Daiichi Sankyo Europe GmbH
Acute Myeloid Leukemia
1 trial -
Raludotatug Deruxtecan
Daiichi Sankyo Europe GmbH
Advanced/metastatic solid tumors including gynecological cancers (endometrial cancer, cervical cancer, and nonhigh- grade serous ovarian cancer) and genitourinary cancers (urothelial cancer and ccRCC)
1 trial -
Valemetostat Tosylate, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Valemetostat Tosylate
Daiichi Sankyo Europe GmbH
Advanced or Metastatic Non-Small Cell Lung Cancer
1 trial -
Valemetostat Tosylate, Valemetostat Tosylate
Daiichi Sankyo Europe GmbH
Relapsed/Refractory Peripheral T-Cell Lymphoma
1 trial -
Evaluating Bioequivalence of a Fixed Dose Combination versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatin.
Daiichi Sankyo Europe GmbH
No medical condition.
1 trial -
Evaluating Bioequivalence of a Fixed Dose Combination versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Atorvastatin.
Daiichi Sankyo Europe GmbH
No medical condition.
1 trial -
Evaluating Bioequivalence of a Fixed Dose Combination versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Rosuvastatin.
Daiichi Sankyo Europe GmbH
No medical condition
1 trial -
Evaluating Bioequivalence of a Fixed Dose Combination versus Tablets of Bempedoic Acid / Ezetimibe and Rosuvastatin.
Daiichi Sankyo Europe GmbH
No medical condition.
1 trial -
First-in-Human Trial of DS3610a in Participants with Advanced Solid Tumors
Daiichi Sankyo Europe GmbH
Advanced Solid Tumors
1 trial -
First-in-Human trial of DS9051b in participants with advanced solid tumors
Daiichi Sankyo Europe GmbH
Advanced or Metastatic Adrenocortical Carcinoma (ACC), Metastatic Castration-resistant Prostate Cancer (CRPC)
1 trial -
First-in-human (FIH) Study of DS-1471a in Subjects with Advanced Solid Tumors
Daiichi Sankyo Europe GmbH
Advanced Solid Tumors
1 trial -
First-in-human Trial of DS-2243a in Participants with Advanced Solid Tumors
Daiichi Sankyo Europe GmbH
Advanced Solid Tumor
1 trial -
Phase 1 trial of valemetostat and darolutamide in mCRPC
Daiichi Sankyo Europe GmbH
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1 trial -
Phase 1b Study of Dato-DXd in Combination with Pembrolizumab with or without Platinum Chemotherapy in Advanced or Metastatic Non-Small Cell Lung Cancer
Daiichi Sankyo Europe GmbH
Non-small cell lung cancer
1 trial -
Study of U3-1402 in subjects with non-small cell lung cancer
Daiichi Sankyo Europe GmbH
METASTATIC OR UNRESECTABLE NON-SMALL CELL LUNG CANCER
1 trial -
Subcutaneous Trastuzumab Deruxtecan Phase 1 Trial.
Daiichi Sankyo Europe GmbH
Advanced Solid Tumor
1 trial -
Trastuzumab Deruxtecan, and pembrolizumab in participants with Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
Daiichi Sankyo Europe GmbH
Locally advanced/metastatic breast or non-small cell lung cancer
1 trial -
Valemetostat Tosylate, DS-8201a, Datopotamab deruxtecan, Valemetostat Tosylate, Valemetostat Tosylate
Daiichi Sankyo Europe GmbH
This study will be a Phase 1b, global, multicenter, open-label, 2-part study of valemetostat in combination with DXd ADCs. The Master Protocol study design contains independent subprotocols, which have been defined by treatment combination and subject population, as follows: Sub-protocol A: Valemetostat in combination with T-DXd in subjects with previously treated, unresectable and/or metastatic HER2-low (immunohistochemistry[IHC] 1+ or IHC 2+/in situ hybridization [ISH]-negative) BC; for details, see Sub-protocol A. Sub-protocol B: Valemetostat in combination with T-DXd in subjects with previously treated, advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma; for details, see Sub-protocol B. Sub-protocol C: Valemetostat in combination with Dato-DXd in subjects with previously treated, locally advanced, unresectable, or metastatic non-squamous NSCLC with or without actionable genomic alteration(s); for details, see Sub-protocol C.
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources